Cargando…
基于ctDNA的MRD检测在早期非小细胞肺癌根治术后的应用价值
Lung cancer is the most common malignant tumor in the world, among which non-small cell lung cancer (NSCLC) accounts for about 85% of the total number of lung cancers. The 5-year overall survial (OS) of radical surgery NSCLC patients ranged from 92% in stage Ⅰa1 to 26% in stage Ⅲb, and the continuou...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695239/ https://www.ncbi.nlm.nih.gov/pubmed/34743498 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.44 |